We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA has approved its first-ever drug for rare, unresectable tumours of the adrenal gland with its decision to authorise Progenics Pharmaceuticals’ radiotherapeutic product Azedra (iobenguane I 131) in the treatment of pheochromocytoma or paraganglioma